Aytu BioPharma Inc
Company Profile
Business description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Contact
7900 East Union Avenue
Suite 920
DenverCO80237
USAT: +1 720 437-6580
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2027
Employees
83
Stocks News & Analysis
stocks
ASX gold miner overvalued despite stronger gold prices
stocks
ASX energy giant undervalued despite commissioning challenges
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,199.70 | 30.70 | 0.33% |
| CAC 40 | 8,405.09 | 53.69 | -0.63% |
| DAX 40 | 25,462.98 | 1.03 | -0.00% |
| Dow JONES (US) | 52,201.60 | 545.72 | -1.03% |
| FTSE 100 | 10,898.16 | 27.14 | 0.25% |
| HKSE | 25,807.92 | 497.07 | 1.96% |
| NASDAQ | 24,737.83 | 139.08 | -0.56% |
| Nikkei 225 | 61,434.19 | 930.73 | -1.49% |
| NZX 50 Index | 13,976.67 | 114.74 | 0.83% |
| S&P 500 | 7,400.19 | 28.59 | -0.38% |
| S&P/ASX 200 | 9,038.60 | 35.10 | 0.39% |
| SSE Composite Index | 3,828.47 | 15.15 | 0.40% |